FDA explains device approval routes

Medical devices do not all reach patients through the same FDA gate. That sounds obvious, but in practice a lot of people still flatten the labels and treat “cleared,” “granted,” and “approved” as if they all mean the same thing. They do not. A May 1 explainer in *Medical Economics* tried to fix that confusion for physicians by walking through the three main FDA routes — 510(k), De Novo, and PMA — and why each one tells you something different about the evidence behind a product. (medicaleconomics.com) ### Why is this confusing in the first place? Drug regulation trained clinicians to expect a familiar story — phased trials, then approval. Devices are different. The FDA uses a risk-based framework, so the path depends on the device’s class and how much control is needed to provide reasonable assurance of safety and effectiveness. That means two products can both be legally marketed and still arrive there through very different evidentiary routes. (fda.gov) ### What does “FDA cleared” usually mean? Usually, it means 510(k). In that pathway, a company does not have to prove a device from scratch the way a PMA applicant does. The company has to show the new device is “substantially equivalent” to a legally marketed predicate device — same intended use, and either the same technological characteristics or differences that do not raise new safety or effectiveness questi(fda.gov)cate. (fda.gov) ### Why does the predicate matter so much? Because the 510(k) route is comparative by design. The evidence question is not simply “does this work?” It is “is this close enough to something already on the market?” That is useful, but it also means the regulatory label alone does not tell you how much independent clinical testing sits behind the product you are holding. The *Medical Economics* piece makes that poin(fda.gov)l. (medicaleconomics.com) ### So what is De Novo? De Novo is the middle lane for novel devices that do not have a legally marketed predicate but are still low to moderate risk. Instead of forcing those products into high-risk PMA just because they are new, FDA can create a new device type and classify it into Class I or II with general controls alone, or general plus special controls. Basically, De Novo is how the agency says, “This is new, but not PMA-level dangerous.” (fda.gov) ### And PMA is the hard one? Yes. PMA is the most stringent route and is used for Class III devices — the highest-risk category, including devices that support life, sustain life, or are otherwise crucial to preventing major harm. FDA says PMA approval requires sufficient valid scientific evidence to assure the device is safe and effective for its intended use. That usually means a much heavier clinical and manufacturing package than 510(k). (fda.gov) ### Does “approved” have a special meaning here? It does. In device regulation, “approved” is tied to PMA. “Cleared” usually points to 510(k). De Novo devices are authorized through a grant order that creates a new classification. Those words are not marketing synonyms — they are clues about what FDA reviewed and how. (fda.gov)th that? Treat the regulatory route as the start of the evaluation, not the end. Check which pathway the device used, what comparator anchored the submission, and whether the clinical setting in the evidence matches your own practice. That is the practical takeaway from the *Medical Economics* explainer, especially for fast-moving fields like ophthalmology and AI-enabled tools. (medicaleconomics.com) ### Bottom line? “FDA cleared” and “FDA approved” are not interchangeable badges of quality. They describe different regulatory judgments — and if you want to know how much evidence really stands behind a device, the route to market is one of the first things to read. (medicaleconomics.com)